Avalon Global Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Avalon Global Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-70,000	Closed	-$3.9M	–	49
2017 Q2	$3.9M	Buy	+70,000	New	+$3.81M	2.18%	18

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Avalon Global Asset Management's BMY Position: Q2 2018 in Review

Avalon Global Asset Management sold out of Bristol-Myers Squibb (BMY) in Q2 2018, closing a stake of 59,290 shares — an estimated $3.75M sold.

Avalon Global Asset Management first reported a position in BMY in Q4 2013 and held it in 18 quarters. The position peaked at $3.78M in Q3 2017. 1,691 funds tracked by Wall St. Rank hold BMY as of Q2 2018.

Avalon Global Asset Management reported no remaining Bristol-Myers Squibb position as of Q2 2018 after selling out during the quarter.
Avalon Global Asset Management sold 59,290 Bristol-Myers Squibb shares in Q2 2018, an estimated $3.75M.
Avalon Global Asset Management first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 18 quarters.
Avalon Global Asset Management's Bristol-Myers Squibb position peaked at $3.78M in Q3 2017.
1,691 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2018.

Based on Avalon Global Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.